Pipeline

Our aim is to develop the right antibody for the right target, ultimately producing a treatment that is safer and more effective for patients with Alzheimer’s disease.

ACU193

ACU193 is the first immunotherapy drug candidate to enter the clinic that was developed to selectively target toxic soluble amyloid beta oligomers (AβOs). As AβOs are an early trigger and persistent driver of Alzheimer’s-associated pathology and neurodegeneration, ACU193 addresses an underlying cause of Alzheimer’s by preventing toxic AβOs from binding to dendritic spines and helping preserve neuronal function.

8-year

collaboration with Merck
(Acumen holds exclusive rights of ACU193)

$3.6 million

Awarded a competitive $3.6 million U01 grant from National Institute of
Aging in 2017.

IPO
July 2021

ticker ABOS
Phase 1

Enrollment Complete
Phase 2

Planning
Phase 3

Planning
Submission

Planning
Approval

Planning

INTERCEPT-AD (NCT04931459)

This study is a phase 1, randomized, single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease

CLICK TO LEARN MORE